Fluoxetine updated on 07-01-2025

Large for gestational age (weight)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18436
R78151		 Lee (Controls exposed to TCAs), 2025 Large for gestational age (birth weight >2 standard deviations above the mean for gestational age) during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.37 [0.62;3.05] C
excluded (control group) 		16/719   10/613 26 719
ref
S18415
R77846		 Lee (Controls unexposed, general pop), 2025 Large for gestational age (birth weight >2 standard deviations above the mean for gestational age) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.85 [0.51;1.41] 16/719   9,744/463,440 9,760 719
ref
S7693
R22805		 Kivistö, 2016 Large for gestational age (birthweight >10th centile) during pregnancy (anytime or not specified) retrospective cohort unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.53 [0.16;1.73] -/51   2,191/24,402 - 51
ref
Total 2 studies 0.79 [0.50;1.26] 9,760 770
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Lee (Controls unexposed, general pop), 2025Lee, 2025 1 0.85[0.51; 1.41]9,76071985%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Kivistö, 2016Kivistö, 2016 0.53[0.16; 1.73]-5115%ROB confusion: seriousROB selection: criticalROB classification: moderateROB missing: criticalROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 0.79[0.50; 1.26]9,7607700.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, general pop;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.79[0.50; 1.26]9,7607700%NALee (Controls unexposed, general pop), 2025 Kivistö, 2016 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.79[0.50; 1.26]9,7607700%NALee (Controls unexposed, general pop), 2025 Kivistö, 2016 2 Tags Adjustment   - Yes  - Yes 0.79[0.50; 1.26]9,7607700%NALee (Controls unexposed, general pop), 2025 Kivistö, 2016 2 Monotherapy   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 0.79[0.50; 1.26]9,7607700%NALee (Controls unexposed, general pop), 2025 Kivistö, 2016 2 All studiesAll studies 0.79[0.50; 1.26]9,7607700%NALee (Controls unexposed, general pop), 2025 Kivistö, 2016 20.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 18436

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.79[0.50; 1.26]11,9427700%NALee (Controls unexposed, general pop), 2025 Kivistö, 2016 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.37[0.62; 3.05]26719 -NALee (Controls exposed to TCAs), 2025 10.510.01.0